Results show potential of J&J’s TAR-210 to transform treatment of bladder cancer with FGFR alterations Read more
J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s growing investment trend: GlobalData Read more
J&J’s Akeega FDA approval to heat up PARP battle with dual-action treatment for prostate cancer: GlobalData Read more
Top 20 global biopharma companies report 2.3 per cent market cap growth in Q2 2023: GlobalData Read more
J&J and Momenta Pharma file patent infringement lawsuit against Natco, Mylan Pharma and others Read more
